Amid ice and snow, a blazing flame atop a newly unveiled cauldron marked the opening of the 9th Asian Winter Games in Harbin, Heilongjiang province, on Feb. 7. The torch tower was designed by teachers ...

The NFL’s Super Bowl LIX brand campaign, NFL Flag 50, which is set to debut directly after the Apple Music Halftime Show, is ...

Introducing London Experience Week (LXW), the world's first-ever city-wide celebration of the booming Experience Economy, running from April 28 to May 2, 2025.

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

So, accumulating at current levels will not make sense. Exit and accept the loss. Mankind Pharma (₹2,518.40): The long-term trend is up. Within that, the stock is in a corrective fall.

It has upgraded the ratings of 24 companies in its pharma portfolio since April 2024, on account of a continued improvement in the business and financial profile, high operating cash flow conversion, ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...